Rev-erbα/β gene in cardiac cells mediates a normal metabolic rhythm that enables the cells to prefer lipids as a source of energy during the animal’s resting time, daytime for mice.
Removing Rev-erbα/β disrupts this rhythm, reduces the cardiomyocytes’ ability to use lipids in the resting time, and leads to progressive dilated cardiomyopathy and lethal heart failure.
“We studied how the Rev-erbα/β gene influenced the metabolism of the heart by knocking it out specifically in mouse cardiomyocytes,” said co-corresponding author Dr. Zheng Sun, associate professor of medicine, a section of endocrinology, diabetes, and metabolism and of molecular and cellular biology at Baylor.
To learn how Rev-erbα/β mediated its effects, the team analyzed gene and protein expression and a comprehensive panel of metabolites and lipids, during both the awake and sleep hours.
They found that the Rev-erbα/β gene is highly expressed only during the sleep hours, and its activity is associated with fat and sugar metabolisms.
In the resting phase, which for humans is at night, and for mice in the day, the heart uses fatty acids that are released from fats as the main source of energy.
In the active phase, which is during the day for people and at night for mice, the heart has some resistance to dietary carbohydrates.
Researchers found that without Rev-erbα/β, hearts have metabolic defects that limit the use of fatty acids when resting, and there is overuse of sugar in the active phase.
To test this hypothesis, the researchers determined whether restoring the defect in fatty acid use would improve the condition.
They fed Rev-erbα/β knockout mice one of two high-fat diets. One diet was mostly high-fat. The other was a high-fat/high-sucrose diet, resembling human diets that promote obesity and insulin resistance. The high-fat/high-sucrose diet partially alleviated the cardiac defects, but the high-fat diet did not.
These findings support that the metabolic defect that prevents the heart cells from using fatty acids as fuel is causing the majority of the cardiac dysfunction.
Later, researchers analyzed the molecular clock function in heart tissues of patients with dilated cardiomyopathy who had received heart transplants to explore whether the clock function was associated with the severity of cardiac dilation in humans.
Tissue samples were taken at different times of the day and the ratio of the gene expression of the circadian genes Rev-erbα/β and Bmal1 was calculated providing a chronotype. They found that the heart chronotype correlates with the severity of cardiac dilation.
Finally, the researchers explored the possibility of pharmacologically manipulating fatty acid and sugar metabolism to improve the condition.
They found that while medications can help restore the altered metabolic pathways, it was important to give the drugs aligned with the internal circadian rhythm of the corresponding metabolic pathways.
If the drugs were given out-of-sync with the pathway they were intended to restore, the treatment did not improve the cardiac condition.
These findings highlight the importance of chronotherapy, the scheduling of medications according to the circadian rhythm, not just in this study, but for many other medications.
Source: Medindia
